Tellus Therapeutics

Tellus Therapeutics

Biotechnology, 517 Summit Trail Dr, Durham, North Carolina, 27278, United States, 1-10 Employees

tellustherapeutics.com

  • twitter
  • LinkedIn

phone no Phone Number: 91********

Who is TELLUS THERAPEUTICS

Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus' lead candidate, TT-20, i...

Read More

map
  • 517 Summit Trail Dr, Durham, North Carolina, 27278, United States Headquarters: 517 Summit Trail Dr, Durham, North Carolina, 27278, United States
  • 2018 Date Founded: 2018
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 7389

checked-icon Does something look wrong? Fix it. | View contact records from TELLUS THERAPEUTICS

Tellus Therapeutics Org Chart and Mapping

Employees

Jaron Ballentine

VP Clinical Operations and Business Development

Eric Benner

Co-Founder, Chief Scientific Officer

Austin Schwartz

VP of Operations and Finance

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Tellus Therapeutics

Answer: Tellus Therapeutics's headquarters are located at 517 Summit Trail Dr, Durham, North Carolina, 27278, United States

Answer: Tellus Therapeutics's phone number is 91********

Answer: Tellus Therapeutics's official website is https://tellustherapeutics.com

Answer: Tellus Therapeutics's revenue is $1 Million to $5 Million

Answer: Tellus Therapeutics's SIC: 7389

Answer: Tellus Therapeutics has 1-10 employees

Answer: Tellus Therapeutics is in Biotechnology

Answer: Tellus Therapeutics contact info: Phone number: 91******** Website: https://tellustherapeutics.com

Answer: Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus' lead candidate, TT-20, induces regeneration of myelin-producing oligodendrocytes, reverses white matter injury in an animal models of perinatal brain injury and multiple sclerosis and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access